Systematic review of psychosocial outcomes for patients with advanced melanoma
- 7 November 2016
- journal article
- review article
- Published by Wiley in Psycho-Oncology
- Vol. 26 (11) , 1722-1731
Abstract
Background: New advanced melanoma therapies are associated with improved survival; however, quality of survivorship, particularly psychosocial outcomes, for patients overall and those treated with newer therapies is unclear.Objective: Synthesize qualitative and quantitative evidence about psychosocial outcomes for advanced (stage III/IV) melanoma patients.Methods: Five databases were searched (01/01/1980 to 31/01/2016). Inclusion criteria were as follows: advanced melanoma patients or sub‐group analysis; assessed psychosocial outcomes; and English language.Results: Fifty‐two studies met review criteria (4 qualitative, 48 quantitative). Trials comprise mostly medical not psychosocial interventions, with psychosocial outcomes assessed within broader quality of life measures. Patients receiving chemotherapy or IFN‐alpha showed decreased emotional and social function and increased distress. Five trials of newer therapies appeared to show improvements in emotional and social function. Descriptive studies suggest that patients with advanced, versus localized disease, had decreased emotional and social function and increased distress. Contributors to distress were largely unexplored, and no clear framework described coping/adjustment trajectories. Patients with advanced versus localized disease had more supportive care needs, particularly amount, quality, and timing of melanoma‐related information, communication with and emotional support from clinicians. Limitations included: lack of theoretical underpinnings guiding study design; inconsistent measurement approaches; small sample sizes; non‐representative sampling; and cross‐sectional design.Conclusions: Quality trial evidence is needed to clarify the impact of treatment innovations for advanced melanoma on patients' psychosocial well‐being. Survivorship research and subsequent translation of that knowledge into programs and services currently lags behind gains in the medical treatment of advanced melanoma, a troubling circumstance that requires immediate and focused attention.Keywords
This publication has 65 references indexed in Scilit:
- Screening for Distress in Routine Oncological Care—A Survey in 520 Melanoma PatientsPLOS ONE, 2013
- Predictors of skin self-examination before and after a melanoma diagnosis: the role of medical advice and patient’s level of educationInternational Archives of Medicine, 2013
- A systematic review of the impact of stigma and nihilism on lung cancer outcomesBMC Cancer, 2012
- Psychosocial aspects of post‐treatment follow‐up for stage I/II melanoma: a systematic review of the literaturePsycho-Oncology, 2012
- A randomised clinical trial of the effects of spiritually focused meditation for people with metastatic melanomaMental Health, Religion & Culture, 2012
- Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatmentHealth and Quality of Life Outcomes, 2012
- The IPOS New International Standard of Quality Cancer Care: integrating the psychosocial domain into routine carePsycho-Oncology, 2011
- A systematic review of health-related quality of life in cutaneous melanomaAnnals of Oncology, 2009
- Perception of burden experienced during diagnostic tests by melanoma patients with lymph node metastasesMelanoma Research, 2009
- Anxiety and depressive symptoms at different stages of malignant melanomaPsycho-Oncology, 1992